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Abstract
The clinical problem of bladder cancer is its high recurrence and progression, and that the most
sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient
compliance. Biomarkers for recurrence and progression could make a great contribution, but in
spite of decades of research, no biomarkers are commercially available with the requisite sensitivity
and specificity. In the post-genomic age, the means to search the entire genome for biomarkers has
become available, but the conventional approaches to biomarker discovery are entirely inadequate
to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity
and specificity equal to that of cystoscopy is a problem of systems biology.
Bladder cancer is the most expensive cancer to manage
from diagnosis to death from any cause [1], mainly
because bladder cancer also is one of the most recurrent
cancers, with some studies showing over half of patients
will recur within 5 years [2]. The most widely held etio-
logic hypothesis is that superficial bladder cancer arises
from mutations in fibroblastic growth factor 2 receptor
and ras signaling, whereas the aggressive track has been
thought to arise from mutations in the p53 and Rb signal-
ing system [3]. Even though over 75% of bladder cancers
are superficial at initial diagnosis, the problem of recur-
rence is particularly insidious because some 15 to 25% of
patients progress to aggressive invasive disease [3] that
may be responsible for half the deaths from bladder can-
cer. Poor patient compliance with cystoscopic monitoring
begs for noninvasive biomarkers with sensitivity near
95%. Anything less than 95% sensitivity is asking patients
to bet their lives on a test with worse sensitivity than the
routine "gold standard" of cystoscopy. No product has
reached the commercial market that meets these criteria
[4]. Screening of high risk populations, such as smokers or
workers exposed to industrial bladder carcinogens,
requires high specificity to control costs but can be cost-
effective even when sensitivity is 50% or less [5,6]. Prog-
nostic markers to detect disease that is progressing need to
emphasize sensitivity over specificity.
Because urine is readily available and contains both cells
exfoliated from the normal and pathological urothelium
as well as proteins from either secretion or cell lysis, blad-
der cancers have been early targets for biomarker develop-
ment. Historically, tumor-associated antigens (TAA) and
markers of abnormal ploidy using exfoliated cells were
targeted. Cytology itself, although highly specific, lacks
sensitivity [4]. Some of the TAA biomarkers such as M344,
DD23 and 19A211 achieved excellent sensitivity when
combined with abnormal ploidy markers such as chromo-
somal loss or rare event cells with > 5C DNA. Quantitative
fluorescence image analysis techniques combining two or
three markers have actually reached the requisite sensitiv-
ity and specificity [7]. Technology platforms have been
barriers to commercialization because quantitation and
rare event detection were both seen as keys to improving
sensitivity and specificity, and until recently the technol-
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ogy for quantitative fluorescence microscopy has not been
widely available.
Several products designed to detect proteins in urine have
reached commercialization as dipstick tests. While these
are cheap and convenient, the sensitivity tends to be insuf-
ficient, about 70% or less [8]. Although such tests might
be useful as screening tests in high-risk populations, the
need to follow up numerous false positives might render
them less than cost effective. As tests for recurrence, a false
sense of security from a negative could be fatal. Thus, the
value of these tests is questionable.
In recent years, the development of microarrays and pro-
teomics has brought the power of whole genome analysis
to the field of biomarkers. Naively, many in the field have
assumed that high-dimension studies of patient samples
will magically yield robust, sensitive and specific biomar-
kers. Misconceptions about the technology and misunder-
standings of the underlying biology of disease have
plagued the field. Instead of there being "pathways" in
which signaling is linear and definable, the reality is a
large, interconnected network of cooperating proteins
that regulate cellular growth, death and differentiation.
Alterations in this network tend to ripple outward in
unpredictable ways. Moreover, this complex system
responds to complex inputs from the local tumor environ-
ment as well as all other biological variables affecting the
organism. Individual molecular markers tend to lack sen-
sitivity and specificity because, unlike morphologically-
based grading, they are imperfectly reflective of the overall
phenotype and overly sensitive to the cellular network. At
a practical level, this means the probability of finding a
single biomarker with the requisite sensitivity and specif-
icity is vanishingly small.
Currently, high dimension studies are used to identify
individual biomarkers that are then preliminarily vali-
dated in small studies [9], as has been done for decades.
However, what is needed is not more studies of individual
biomarkers but rather to determine how biomarkers relate
to other biomarkers and how they can be combined into
practical panels. Surprising to many, practical panels
using large gene number "signatures" are unlikely to come
from high-dimension studies of patient cancer tissues.
This approach as applied to breast cancer was recently cri-
tiqued by Ein-Dor and colleagues, who showed that eight
successive sets of 80 genes performed as well as did the
original 80 chosen because they had the highest correla-
tion with survival [10]. Moreover, such large biomarker
sets tend not to be robust. Every patient's cancer is unique,
and thousands of samples may be required to obtain
robust biomarker panels [11]. Because the number of
unknowns (genes) far exceeds the number of equations
(patients) and the relationships are nonlinear, there are
many solutions. The contributions of other biological var-
iables cannot easily be dissected out, nor are the measure-
ments (gene expression) independent of each other.
Practical biomarker panels need to be constructed from
small numbers of assays that are as independent as possi-
ble and reflective of the overall phenotype, rather than
being a particular molecule that is altered in some fraction
of cancers. In theory, developing a panel that assays all rel-
evant branches of the complex cellular network might be
possible, but this approach would be very difficult. Cau-
sality is manifested in complex ways in systems and the
old assumptions of cause and effect are not adequate
guides to use this new technology. These conclusions will
require a virtual "re-boot" of the approach to biomarker
development.
Perhaps the search for candidate biomarkers needs to be
divorced from the validation in clinical populations. Ana-
lyzing patient samples with high-dimension approaches
and expecting to find the single "magic bullet" biomarker,
or even a small set of effective biomarkers, is unrealistic
for the reasons discussed above. Only in model systems
can reproducible samples be obtained and extraneous
biology controlled. However, the models must be more
realistic than cells cultured on plastic because many of the
features reflecting the complex system of genes and pro-
teins are inactive in cells grown on plastic [12]. Three-
dimensional culture models involving an extracellular
stromal element [12,13] should be more effective. The
value of high-dimension studies of patient cancer speci-
mens is less as discovery tools than as validation tools.
When stored in public databases, they can be used a priori
to test combinations of biomarkers derived independ-
ently from controlled, model system studies. A marker
with 70% sensitivity could be useful if a second marker
could be found that was positive in the marker 1-negative
group who had disease. New mathematical models will be
needed to classify biomarkers into independent or inter-
acting sets using, for example, Bayesian logic trees (logistic
regression) or nonlinear models adapted to large data sets
and incorporating modern post-genomic bioinformatics
and functional genomics that can determine associations
between disease or phenotype and gene/protein expres-
sion [14,15].
After spending huge sums of money over the years on
biomarker research there is remarkably little to show for
the effort. The needs for clinically effective biomarkers for
bladder cancer and other cancers are great, and only a
fresh approach based on the powerful new technologies
available recently are needed. However, along with new
technology must come a new understanding that old par-
adigms are not adequate in the post-genomic age. To sum-
marize, the new paradigm should consist of the following:
further improvement in understanding of the complex,Publish with BioMed Central    and   every 
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interacting system of genes and proteins to be able to
develop relevant tests for dysregulation of the system, fur-
ther development of mathematical techniques to analyze
data within the system paradigm, and a high quality set of
clinical studies using genome-wide techniques that cap-
tures the spectrum of disease. The intelligent development
of biomarkers truly is a problem in systems biology.
References
1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health
economics of bladder cancer: a comprehensive review of the
published literature.  Pharmacoeconomics 2003, 21(18):1315-1330.
2. Amling CL: Diagnosis and management of superficial bladder
cancer.  Curr Probl Cancer 2001, 25(4):219-278.
3. Wu XR: Urothelial tumorigenesis: a tale of divergent path-
ways.  Nat Rev Cancer 2005, 5(9):713-725.
4. Simon MA, Lokeshwar VB, Soloway MS: Current bladder cancer
tests: unnecessary or beneficial?  Crit Rev Oncol Hematol 2003,
47(2):91-107.
5. Lotan Y, Svatek RS, Sagalowsky AI: Should we screen for bladder
cancer in a high-risk population?: A cost per life-year saved
analysis.  Cancer 2006, 107(5):982-990.
6. Svatek RS, Sagalowsky AI, Lotan Y: Economic impact of screening
for bladder cancer using bladder tumor markers: a decision
analysis.  Urol Oncol 2006, 24(4):338-343.
7. Hemstreet GP3, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, et al.:
Biomarker Risk Assessment and Bladder Cancer Detection
in a Cohort Exposed to Benzidine.  J Natl Cancer Inst 2001,
93(6):427-436.
8. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from
hematuria to molecular diagnostics – where do we stand?
Expert Rev Anticancer Ther 2008, 8(7):1111-1123.
9. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR: Cystatin
B as a tissue and urinary biomarker of bladder cancer recur-
rence and disease progression.  Clin Cancer Res 2009,
15(3):1024-1031.
10. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature
genes in breast cancer: is there a unique set?  Bioinformatics
2005, 21(2):171-178.
11. Ein-Dor L, Zuk O, Domany E: Thousands of samples are needed
to generate a robust gene list for predicting outcome in can-
cer.  Proc Natl Acad Sci USA 2006, 103(15):5923-5928.
12. Dozmorov MG, Kyker KD, Hauser PJ, Saban R, Buethe DD, Doz-
morov IM, et al.: From microarray to biology: An integrated
experimental, statistical and in silico analysis of how the
extracellular matrix modulates the phenotype of cancer
cells.  Bioinformatics 2008, 9(9):S4.
13. Hurst RE, Kyker KD, Bonner RB, Bowditch RG, Hemstreet GP:
Matrix-Dependent Plasticity of the Malignant Phenotype of
Bladder Cancer Cells.  Anticancer Res 2003, 23(4):3119-3128.
14. Clark TG, De IM, Griffiths RC: Bayesian logistic regression using
a perfect phylogeny.  Biostatistics 2007, 8(1):32-52.
15. Clark TG, De IM, Griffiths RC, Farrall M: Finding associations in
dense genetic maps: a genetic algorithm approach.  Hum
Hered 2005, 60(2):97-108.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2490/9/1/prepub